Literature DB >> 19551859

Cancer risk among patients with cystic fibrosis and their first-degree relatives.

Marie Johannesson1, Johan Askling, Scott M Montgomery, Anders Ekbom, Shahram Bahmanyar.   

Abstract

Patients with cystic fibrosis (CF) are at increased risk of some cancers. Little is known about the cancer risks among carriers heterozygous for the CF mutation and it is hypothesized this may be associated with reduced cancer risk. Using Swedish general population-based registers, we identified 884 patients with CF from 1968 to 2003 and 3,033 of their first-degree relatives The subjects were followed from birth of index persons or 1958, whichever came later, until death, emigration or 2003, whichever came first. Cancer risks were compared with the general Swedish population using standardized incidence ratios (SIR) with 95% confidence intervals (CI). Patients, followed for an average of 21 years, were at a higher overall risk of cancer. Some 26 cancer diagnoses, after excluding multiple diagnoses of nonmelanoma skin cancer in one man, produced an overall SIR of 3.2 (95% CI 2.1-4.6). We found statistically significantly increased risks for kidney, thyroid, endocrine, lymphoma and nonmelanoma skin cancer. There was no modification of cancer risk among parents and siblings, with an average of 21 years of follow-up. This study did not identify a heterozygote advantage for CF gene mutations in relation to cancer risk. Copyright (c) 2009 UICC.

Entities:  

Mesh:

Year:  2009        PMID: 19551859     DOI: 10.1002/ijc.24679

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Endogenous surface expression of ΔF508-CFTR mediates cAMP-stimulated Cl(-) current in CFTR(ΔF508/ΔF508) pig thyroid epithelial cells.

Authors:  Yonghai Li; Suhasini Ganta; Peying Fong
Journal:  Exp Physiol       Date:  2011-09-23       Impact factor: 2.969

Review 2.  The Enigmatic Gut in Cystic Fibrosis: Linking Inflammation, Dysbiosis, and the Increased Risk of Malignancy.

Authors:  Millie Garg; Chee Y Ooi
Journal:  Curr Gastroenterol Rep       Date:  2017-02

3.  Gastrointestinal surgery in adult patients with cystic fibrosis.

Authors:  Abhiram Sharma; Alison Morton; Daniel Peckham; David Jayne
Journal:  Frontline Gastroenterol       Date:  2012-07-13

4.  Association of CFTR gene polymorphisms with papillary thyroid cancer.

Authors:  In-Hwan Oh; Changmo Oh; Tai-Young Yoon; Joong-Myung Choi; Su Kang Kim; Hae Jeong Park; Young Gyu Eun; Dae Han Chung; Kee Hwan Kwon; Bong-Keun Choe
Journal:  Oncol Lett       Date:  2011-11-15       Impact factor: 2.967

Review 5.  Cystic fibrosis transmembrane conductance regulator-emerging regulator of cancer.

Authors:  Jieting Zhang; Yan Wang; Xiaohua Jiang; Hsiao Chang Chan
Journal:  Cell Mol Life Sci       Date:  2018-02-06       Impact factor: 9.261

6.  Cancer risk among lung transplant recipients with cystic fibrosis.

Authors:  Aliza K Fink; Elizabeth L Yanik; Bruce C Marshall; Michael Wilschanski; Charles F Lynch; April A Austin; Glenn Copeland; Mahboobeh Safaeian; Eric A Engels
Journal:  J Cyst Fibros       Date:  2016-08-15       Impact factor: 5.527

Review 7.  Role of ion channels in gastrointestinal cancer.

Authors:  Kyle J Anderson; Robert T Cormier; Patricia M Scott
Journal:  World J Gastroenterol       Date:  2019-10-14       Impact factor: 5.742

Review 8.  What Role Does CFTR Play in Development, Differentiation, Regeneration and Cancer?

Authors:  Margarida D Amaral; Margarida C Quaresma; Ines Pankonien
Journal:  Int J Mol Sci       Date:  2020-04-29       Impact factor: 5.923

9.  Metastatic bladder cancer presenting with persistent hematuria in young man with cystic fibrosis.

Authors:  Premal Patel; Harvey R Rabin; Michael M Vickers; Michael D Parkins
Journal:  Case Rep Pulmonol       Date:  2013-05-14

10.  Malignancies in patients with cystic fibrosis: a case series.

Authors:  Dorothea Appelt; Teresa Fuchs; Gratiana Steinkamp; Helmut Ellemunter
Journal:  J Med Case Rep       Date:  2022-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.